We are live on
!
Find out more
CA
CHI Advisors Portfolio holdings
AUM
$252M
1-Year Est. Return
56.99%
This Fund
S&P 500
This Quarter
Est. Return
-26.85%
1 Year Est. Return
+56.99%
3 Year Est. Return
+88.23%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$235M
AUM Growth
-$66.1M
(-22%)
Cap. Flow
+$31.7M
Cap. Flow
% of AUM
13.5%
Top 10 Holdings %
Top 10 Hldgs %
83.33%
Holding
22
New
2
Increased
11
Reduced
3
Closed
–
Avg Time Held Equity + Options
5.8
quarters
Top 10 Avg Time Held Equity + Options
3.4
quarters
Top 20 Avg Time Held Equity + Options
5.9
quarters
Avg Time Held Equity only
6
quarters
Top 10 Avg Time Held Equity only
3.4
quarters
Top 20 Avg Time Held Equity only
5.9
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
2seventy bio
TSVT
|
+$13.9M |
| 2 |
Repare Therapeutics
RPTX
|
+$5.47M |
| 3 |
Cullinan Oncology
CGEM
|
+$3.73M |
| 4 |
FRLN
Freeline Therapeutics Holdings plc American Depositary Shares
FRLN
|
+$3.69M |
| 5 |
G1 Therapeutics, Inc. Common Stock
GTHX
|
+$2.45M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
|
+$6.61M |
| 2 |
ORTX
Orchard Therapeutics plc American Depositary Shares
ORTX
|
+$1.12M |
| 3 |
Compass Therapeutics
CMPX
|
+$401K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.91% |
| 2 | Miscellaneous | 0.09% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
RXDX
1
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
| $59.9M | 25.45% |
1,585,096
-167,147
| -10% | -$6.61M |
2021 Q1
4 quarters
|
|
|
2
DELISTED
Repare Therapeutics
RPTX
| $36.8M | 15.63% |
2,581,097
+368,841
| +17% | +$5.47M |
2020 Q2
7 quarters
|
|
|
3
Cullinan Oncology
CGEM
$962M
| $28.8M | 12.26% |
2,753,047
+276,327
| +11% | +$3.73M |
2021 Q1
4 quarters
|
|
4
Pliant Therapeutics
PLRX
$61.1M
| $18.6M | 7.92% |
2,657,457
+87,978
| +3% | +$898K |
2020 Q2
7 quarters
|
|
|
VECT
5
DELISTED
VectivBio Holding AG Ordinary Shares
VECT
| $14.5M | 6.18% |
3,084,310
+408,902
| +15% | +$2.14M |
2021 Q2
3 quarters
|
|
|
6
DELISTED
2seventy bio
TSVT
| $14M | 5.95% |
+819,672
| New | +$13.9M |
2022 Q1
0 quarters
|
|
7
DELISTED
Omega Therapeutics, Inc. Common Stock
OMGA
| $6.59M | 2.8% |
1,055,882
| – | – |
2021 Q3
2 quarters
|
|
8
Larimar Therapeutics
LRMR
$263M
| $6.14M | 2.61% |
1,515,148
| – | – |
2020 Q2
7 quarters
|
|
|
FRLN
9
DELISTED
Freeline Therapeutics Holdings plc American Depositary Shares
FRLN
| $5.45M | 2.32% |
324,155
+199,062
| +159% | +$3.69M |
2020 Q3
6 quarters
|
|
10
DELISTED
Kezar Life Sciences
KZR
| $5.23M | 2.22% |
31,461
+4,236
| +16% | +$608K |
2019 Q3
10 quarters
|
|
11
ImageneBio Inc
IMA
$48.2M
| $4.97M | 2.11% |
67,896
| – | – |
2021 Q1
4 quarters
|
|
|
ONCR
12
DELISTED
Oncorus, Inc.
ONCR
| $4.3M | 1.83% |
2,417,436
+310,533
| +15% | +$870K |
2020 Q4
5 quarters
|
|
|
AKUS
13
DELISTED
Akouos Inc
AKUS
| $3.97M | 1.69% |
836,120
| – | – |
2020 Q2
7 quarters
|
|
|
14
Compass Therapeutics
CMPX
$169M
| $3.88M | 1.65% |
2,829,712
-193,980
| -6% | -$401K |
2021 Q4
1 quarter
|
|
|
ORTX
15
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
| $3.78M | 1.61% |
530,775
-114,211
| -18% | -$1.12M |
2019 Q3
10 quarters
|
|
|
16
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
| $3.71M | 1.58% |
488,635
+258,635
| +112% | +$2.45M |
2020 Q2
7 quarters
|
|
17
DELISTED
Inozyme Pharma
INZY
| $3.65M | 1.55% |
892,057
| – | – |
2020 Q3
6 quarters
|
|
18
Keros Therapeutics
KROS
$230M
| $3.38M | 1.44% |
62,229
+44,711
| +255% | +$2.3M |
2020 Q2
7 quarters
|
|
19
Corvus Pharmaceuticals
CRVS
$845M
| $2.79M | 1.19% |
1,703,137
+1,303,137
| +326% | +$2.39M |
2019 Q3
10 quarters
|
|
20
Ovid Therapeutics
OVID
$471M
| $2.68M | 1.14% |
852,888
+452,888
| +113% | +$1.42M |
2019 Q3
10 quarters
|
|
21
Precision BioSciences
DTIL
$180M
| $1.87M | 0.79% |
20,221
| – | – |
2019 Q3
10 quarters
|
|
22
PUT
State Street SPDR S&P Biotech ETF
XBI
$10B
| $206K | 0.09% |
+222,500
| New | +$20.5M |
2022 Q1
0 quarters
|
|
Similar funds
SC
T
W
RBGI
TOGEPT
IAM
RCGI
AEPLI
CHI Advisors's Q1 2022 Portfolio in Review
As of Q1 2022, CHI Advisors held 22 positions worth $235M, down 22% from $301M the previous quarter. Its ten largest holdings account for 83% of the portfolio.
CHI Advisors deployed $31.7M of net new capital in Q1 2022, opening 2 new positions and adding to 11 existing holdings. Its largest new stake was 2seventy bio: 819,672 shares worth $14M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Miscellaneous.
On the sell side, the largest reduction was Prometheus Biosciences, Inc. Common Stock, an estimated $6.61M trimmed.
- CHI Advisors's largest Q1 2022 buy was 2seventy bio: 819,672 shares worth $14M.
- CHI Advisors added most to Repare Therapeutics in Q1 2022, an estimated $5.47M increase.
- CHI Advisors's biggest Q1 2022 reduction was Prometheus Biosciences, Inc. Common Stock, cutting an estimated $6.61M.
- CHI Advisors's ten largest holdings make up 83% of its $235M portfolio in Q1 2022.
- CHI Advisors opened 2 new positions and closed 0 in Q1 2022.
- CHI Advisors's portfolio value fell 22% quarter-over-quarter to $235M.
Based on CHI Advisors's 13F filing for Q1 2022, filed 16 May 2022.